Temozolomide Injection

DRUG2 trials

Sponsors

Peking University Cancer Hospital & Institute, First Affiliated Hospital of Zhejiang University

Conditions

Malignant MelanomaMelanoma

Phase 2

Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma

Peking University Cancer Hospital & InstituteMelanoma

Start: 2020-05-31End: 2023-02-28Target: 40Updated: 2020-05-21

A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma

First Affiliated Hospital of Zhejiang UniversityMalignant Melanoma

Start: 2021-03-07End: 2024-09-07Target: 90Updated: 2021-05-13

Related Papers

Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma.

2025-05-011 citations

Camrelizumab plus apatinib and temozolomide as first-line therapy for advanced acral melanoma: 2-year survival results from CAP 03.

Journal of Clinical Oncology2024-06-01

Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma

JAMA Oncology2023-06-0124 citations

A phase II clinical trial of camrelizumab (CAM, an IgG4 antibody against PD-1) combined with apatinib (APA, a VEGFR-2 tyrosine kinase inhibitor) and temozolomide (TMZ) as the first-line treatment for patients (pts) with advanced acral melanoma (AM).

Journal of Clinical Oncology2022-06-015 citations